Skip to content
Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
The rare disease patient community is the beating heart of the Biotechnology Innovation Organization’s (BIO) mission. Whether it is driving policy that supports innovation, […]
BIO 2025: Rare disease patients can’t wait Read More »
Day 1 of BIO 2025 was all about collaboration: how industry can collaborate with the U.S. government to advance biodefense, how collaboration is key
BIO 2025: A few highlights from Day 1 Read More »
The One Big Beautiful Bill Act – the “reconciliation bill” being considered by Congress – features policies that are crucial for driving American innovation.
Legislation introduced by Senators John Barrasso (R-WY) and Martin Heinrich (D-NM) would help protect the research and development of new treatments for patients with
Senators introduce bipartisan bill to protect new medicines for rare disease Read More »
Now that vaccines have all but eliminated smallpox, measles, polio, and other childhood scourges in the U.S., it seems easy to forget that these
BIO campaign urges: ‘Invest in America. Vaccinate’ Read More »
February 28 is Rare Disease Day, and in observance, the Biotechnology Innovation Organization (BIO) is highlighting how it is working with member companies to
BIO celebrates release of FDA Rare Disease Innovation Hub 2025 strategic plan Read More »
Drug development in the rare disease space has seen a vast amount of innovation in recent years, with a number of groundbreaking therapies coming
Goodwin Rare Disease Symposium: ‘So much opportunity, so much unmet need’ Read More »
“This is America,” goes the musical refrain of the new Hims & Hers Super Bowl ad for its compounded obesity drugs. But Hims &
What the Hims & Hers Super Bowl commercial gets wrong about innovation… and America Read More »
Reforms to prevent middlemen from driving up drug prices and legislation encouraging the development of oral medications and rare disease treatments were called top
What BIO’s watching in the new Congress Read More »
The increased interest in JPM Week this year is an indication of an improved dealmaking environment for biotech, according to experts for the Biotechnology
Buzz around JPM Week partnering bodes well for biotech dealmaking, BIO says Read More »
